[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
November 2015

Assessment of Botulinum Toxin Aesthetic OutcomesClinical Study vs Real-World Practice

Author Affiliations
  • 1Department of Dermatology, University of California, San Francisco, San Francisco
  • 2Divisions of Otolaryngology and Dermatology, Department of Ophthalmology, Vanderbilt University Medical Center, Nashville, Tennessee
  • 3Manhattan Eye, Ear & Throat Hospital, New York, New York
JAMA Dermatol. 2015;151(11):1177-1178. doi:10.1001/jamadermatol.2015.2881

Thirty years ago, few of us could have envisioned today’s practice of aesthetic medicine. Led by botulinum toxin type A (BoNTA), innovation in facial injectables has revolutionized our practices. New technologies are poised to further expand aesthetic treatment opportunities in the near future. To fuel continued progress, regulatory bodies must accurately reflect the knowledge and best practices shaped from the research and experience of the past 3 decades.

Aesthetic medicine is unique; clinical success is inextricably linked to patient perception and preference. Whereas eradication of acne lesions or squamous cell carcinomas is easily quantified in medical dermatology, optimal outcomes in aesthetic medicine are not as objectively defined.

First Page Preview View Large
First page PDF preview
First page PDF preview
×